• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2025, Vol. 42 ›› Issue (1): 73-77.

• 药品评价 • 上一篇    下一篇

复发性流产患者应用孕康颗粒联合黄体酮治疗的效果及安全性分析

李清, 张小环, 张方圆   

  1. 南阳市中心医院, 河南 南阳 473000
  • 收稿日期:2025-01-09 修回日期:2025-02-08 出版日期:2025-02-28 发布日期:2025-02-28

Analysis of the Efficacy and Safety of Yunkang Granules Combined with Progesteron in the Treatment of Recurrent Abortion Patients

  1. Nanyang Central Hospital, Henan Nanyang 473000, China
  • Received:2025-01-09 Revised:2025-02-08 Online:2025-02-28 Published:2025-02-28

摘要: 目的:分析孕康颗粒联合黄体酮治疗复发性流产患者的效果及安全性。方法:回顾性选取2021年12月至2023年4月南阳市中心医院接收的106例复发性流产患者为研究对象,依据不同治疗方案分为常规组、联合组,各53例。常规组接受黄体酮治疗,联合组接受黄体酮+孕康颗粒治疗。比较两组临床疗效、安全性、妊娠结局,治疗前后中医证候积分(阴道出血、腰酸腹痛、头晕耳鸣、畏寒肢冷)、雌二醇(E2)、孕酮、人绒毛膜促性腺激素(β-HCG)、D-二聚体(D-D)、活化部分凝血酶原时间(APTT)、纤溶酶原激活抑制剂-1(PAI-1)、组织型纤溶酶原激活剂(t-PA)、凝血酶原时间(PT)水平。结果:联合组临床疗效94.34%高于常规组81.13%(P<0.05);治疗后联合组腰酸腹痛、阴道出血、畏寒肢冷、头晕耳鸣积分均低于常规组(P<0.05);治疗后联合组β-HCG、E2、孕酮水平高于常规组(P<0.05);治疗后联合组PAI-1、D-D、t-PA水平较常规组更低,APTT、PT水平较常规组更高(P<0.05);联合组不良反应发生率5.66%(3/53)与常规组9.43%(5/53)相比差异无统计学意义(P>0.05);随访9个月,联合组妊娠成功率89.80%高于常规组74.47%(P<0.05)。结论:孕康颗粒联合黄体酮治疗复发性流产安全有效,能调节性激素水平,改善临床症状及凝血功能,提高妊娠成功率。

关键词: font-size:medium, ">孕康颗粒;黄体酮;复发性流产;安全性

Abstract: Objective: To analyze the efficacy and safety of Yunkang Granules combined with progesterone in the treatment of patients with recurrent abortion. Methods: Retrospectively selected 106 patients with recurrent miscarriage received by Nanyang Downtown Hospital from December 2021 to April 2023 as the study object, and divided into conventional group and combined group based on different treatment programs, each with 53 cases.The conventional group received progesterone treatment, while the combined group received progesterone+ Yunkang Granules.The clinical efficacy, safety, and pregnancy outcomes of the two groups were compared, as well as the TCM syndrome scores(vaginal bleeding, waist pain, abdominal pain, dizziness, tinnitus, and cold limbs), estradiol(E2), progesterone, human chorionic gonadotropin(β-HCG), D-dimer(D-D), activated partial thromboplastin time(APTT), plasminogen activator inhibitor-1(PAI-1), tissue-type plasminogen activator(t-PA), and prothrombin time(PT)levels before and after treatment. Results:The clinical efficacy of the combined group was 94.34%, which was higher than that of the conventional group’s 81.13%(P<0.05).After treatment, the scores of waist pain, abdominal pain, vaginal bleeding, cold limbs, dizziness and tinnitus in the combined group were lower than those in the conventional group(P<0.05).After treatment, the levels of β-HCG, E2, and progesterone in the combined group were higher than those in the conventional group(P<0.05).After treatment, the levels of PAI-1, D-D, and t-PA in the combined group were lower than those in the conventional group, while the levels of APTT and PT were higher than those in the conventional group(P<0.05).The incidence of adverse reactions in the combined group was 5.66%(3/53), which was not significantly different from the conventional group′s 9.43%(5/53)(P>0.05).After a 9 months follow-up, the pregnancy success rate in the combined group was 89.80%, which was higher than the 74.47% in the conventional group(P<0.05). Conclusion: The combination of Yunkang Granules and progesterone is safe and effective for treating recurrent miscarriage.It can regulate sex hormone levels, improve clinical symptoms and coagulation function, and enhance pregnancy success rates.

Key words: font-size:medium, ">Yunkang Granules; Progesterone; Recurrent abortion; Safety

中图分类号: